Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Malignant Melanoma

  Free Subscription

Articles published in Clin Cancer Res

Retrieve available abstracts of 108 articles:
HTML format

Single Articles

    May 2024
  1. EMBABY A, Huijberts SCFA, Wang L, Leite de Oliveira R, et al
    A proof-of-concept study of sequential treatment with the HDAC inhibitor vorinostat following BRAF and MEK inhibitors in BRAFV600mutated melanoma.
    Clin Cancer Res. 2024 May 13. doi: 10.1158/1078-0432.CCR-23-3171.
    PubMed     Abstract available

    January 2024
  2. ANDERSON TM, Chang BH, Huang AC, Xu X, et al
    FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma.
    Clin Cancer Res. 2024 Jan 24:OF1-OF10. doi: 10.1158/1078-0432.CCR-23-2390.
    PubMed     Abstract available

    November 2023
  3. SHEN A, Arbesman M, Lodha R, Rayman P, et al
    Clinical and Immunologic Features of Germline Pathogenic Variant (gPV) Positive Patients with Melanoma.
    Clin Cancer Res. 2023 Nov 30. doi: 10.1158/1078-0432.CCR-23-1964.
    PubMed     Abstract available

    October 2023
  4. PATEL SP, Othus M, Chae YK, Dennis MJ, et al
    A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic neoplasia.
    Clin Cancer Res. 2023 Oct 26. doi: 10.1158/1078-0432.CCR-23-2293.
    PubMed     Abstract available

  5. ZILA N, Eichhoff OM, Steiner I, Mohr T, et al
    Proteomic profiling of advanced melanoma patients to predict therapeutic response to anti-PD-1 therapy.
    Clin Cancer Res. 2023 Oct 20. doi: 10.1158/1078-0432.CCR-23-0562.
    PubMed     Abstract available

  6. MITRA A, Thompson B, Strange A, Amato CM, et al
    A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance.
    Clin Cancer Res. 2023;29:4242-4255.
    PubMed     Abstract available

    CD4+ TIL to the Rescue of Anti-PD-1 Failure by Targeting MHC-II.
    Clin Cancer Res. 2023;29:3829-3831.
    PubMed     Abstract available

    September 2023
  8. MONBERG TJ, Borch TH, Svane IM, Donia M, et al
    TIL Therapy: Facts and Hopes.
    Clin Cancer Res. 2023;29:3275-3283.
    PubMed     Abstract available

    August 2023
  9. VAN DEN BULK J, Verdegaal EME, van der Ploeg M, Visser M, et al
    Neoantigen targetability in progressive advanced melanoma.
    Clin Cancer Res. 2023 Aug 4:CCR-23-1106. doi: 10.1158/1078-0432.CCR-23-1106.
    PubMed     Abstract available

  10. WEISS SA, Sznol M, Shaheen M, Berciano-Guerrero MA, et al
    A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1.
    Clin Cancer Res. 2023 Aug 3:CCR-23-0475. doi: 10.1158/1078-0432.CCR-23-0475.
    PubMed     Abstract available

    July 2023
  11. SMITHY JW, Luke JJ
    CD16+ Macrophages: An Emerging Biomarker for Combined CTLA-4 and PD-1 Blockade.
    Clin Cancer Res. 2023;29:2345-2347.
    PubMed     Abstract available

    June 2023
  12. AUGUSTIN RC, Luke JJ
    PD1 monotherapy reigns supreme in adjuvant melanoma...but for how long?
    Clin Cancer Res. 2023 Jun 28:CCR-23-1194. doi: 10.1158/1078-0432.CCR-23-1194.
    PubMed     Abstract available

  13. ELLINGSEN EB, O'Day S, Mezheyeuski A, Gromadka A, et al
    Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial.
    Clin Cancer Res. 2023 Jun 28:CCR-23-0416. doi: 10.1158/1078-0432.CCR-23-0416.
    PubMed     Abstract available

  14. TOKER J, Iorgulescu JB, Ling AL, Villa GR, et al
    Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors.
    Clin Cancer Res. 2023;29:2226-2238.
    PubMed     Abstract available

  15. FOX BA, Urba WJ, Jensen SM, Page DB, et al
    Cancer's Dark Matter: Lighting the Abyss Unveils Universe of New Therapies.
    Clin Cancer Res. 2023;29:2173-2175.
    PubMed     Abstract available

  16. STINSON JA, Sheen A, Momin N, Hampel J, et al
    Collagen-Anchored Interleukin-2 and Interleukin-12 Safely Reprogram the Tumor Microenvironment in Canine Soft-Tissue Sarcomas.
    Clin Cancer Res. 2023;29:2110-2122.
    PubMed     Abstract available

    May 2023
  17. HOROWITCH B, Lee DY, Ding M, Martinez-Morilla S, et al
    Subsets of interferon signaling predict response to immune checkpoint blockade in melanoma patients.
    Clin Cancer Res. 2023 May 26:CCR-23-0215. doi: 10.1158/1078-0432.CCR-23-0215.
    PubMed     Abstract available

  18. STUPIA S, Heeke C, Bruggemann A, Zaremba A, et al
    HLA class II loss and JAK1/2 deficiency coevolve in melanoma leading to CD4 T cell and IFNgamma cross-resistance.
    Clin Cancer Res. 2023 May 18:CCR-23-0099. doi: 10.1158/1078-0432.CCR-23-0099.
    PubMed     Abstract available

  19. FANE ME, Ecker BL, Kaur A, Marino GE, et al
    Correction: sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients.
    Clin Cancer Res. 2023;29:2012.

  20. DRAGHI A, Presti M, Jensen AWP, Chamberlain CA, et al
    Uncoupling CD4+ TIL-mediated tumor killing from JAK-signaling in melanoma.
    Clin Cancer Res. 2023 May 1:CCR-22-3853. doi: 10.1158/1078-0432.CCR-22-3853.
    PubMed     Abstract available

    April 2023
  21. LARKIN J, Del Vecchio M, Mandala M, Gogas H, et al
    Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238.
    Clin Cancer Res. 2023 Apr 14:CCR-22-3145. doi: 10.1158/1078-0432.CCR-22-3145.
    PubMed     Abstract available

  22. OLSON DJ, Luke JJ
    Myeloid Maturity: ATRA to Enhance Anti-PD-1?
    Clin Cancer Res. 2023;29:1167-1169.
    PubMed     Abstract available

    March 2023
  23. KOTTSCHADE LA, Pond GR, Olszanski AJ, Zakharia Y, et al
    SALVO: Single Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma.
    Clin Cancer Res. 2023 Mar 31:CCR-22-3207. doi: 10.1158/1078-0432.CCR-22-3207.
    PubMed     Abstract available

  24. ROBERT C, Lebbe C, Lesimple T, Lundstrom E, et al
    Phase I Study of Androgen Deprivation Therapy in Combination with Anti-PD-1 in Melanoma Patients Pretreated with Anti-PD-1.
    Clin Cancer Res. 2023;29:858-865.
    PubMed     Abstract available

  25. FENTON GA, Mitchell DA
    Cellular Cancer Immunotherapy Development and Manufacturing in the Clinic.
    Clin Cancer Res. 2023;29:843-857.
    PubMed     Abstract available

    February 2023
  26. BERMAN DM, Bell JI
    Redirecting Polyclonal T Cells against Cancer with Soluble T-Cell Receptors.
    Clin Cancer Res. 2023;29:697-704.
    PubMed     Abstract available

  27. LEE H, Ferguson AL, Quek C, Vergara IA, et al
    Intratumoral CD16+ macrophages are associated with clinical outcomes of patients with metastatic melanoma treated with combination anti-PD-1 and anti-CTLA-4 therapy.
    Clin Cancer Res. 2023 Feb 15:CCR-22-2657. doi: 10.1158/1078-0432.CCR-22-2657.
    PubMed     Abstract available

  28. VON ROEMELING C, Doonan BP, Klippel K, Schultz D, et al
    Oral IRAK-4 inhibitor CA-4948 is blood-brain barrier penetrant and has single-agent activity against CNS lymphoma and melanoma brain metastases.
    Clin Cancer Res. 2023 Feb 7:CCR-22-1682. doi: 10.1158/1078-0432.CCR-22-1682.
    PubMed     Abstract available

    January 2023
  29. LEVI ST, Boland GM
    ONCOS-102: A Step Forward or Sideways?
    Clin Cancer Res. 2023;29:3-4.
    PubMed     Abstract available

    December 2022
  30. BETOF WARNER A, Corrie PG, Hamid O
    Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future.
    Clin Cancer Res. 2022 Dec 9:CCR-22-1922. doi: 10.1158/1078-0432.CCR-22-1922.
    PubMed     Abstract available

  31. WILMOTT JS, Tawbi H, Engh JA, Amankulor NM, et al
    Clinical features associated with outcomes and biomarker analysis of dabrafenib plus trametinib treatment in patients with BRAF-mutant melanoma brain metastases.
    Clin Cancer Res. 2022 Dec 7:CCR-22-2581. doi: 10.1158/1078-0432.CCR-22-2581.
    PubMed     Abstract available

  32. BABIKER H, Borazenci E, Subbiah V, Agarwala S, et al
    Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101).
    Clin Cancer Res. 2022;28:5079-5087.
    PubMed     Abstract available

  33. ANDREWS LP, Cillo AR, Karapetyan L, Kirkwood JM, et al
    Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy.
    Clin Cancer Res. 2022;28:5030-5039.
    PubMed     Abstract available

    November 2022
  34. TOBIN RP, Cogswell DT, Cates VM, Davis DM, et al
    Targeting MDSC differentiation using ATRA: a phase I/II clinical trial combining pembrolizumab and all-trans retinoic acid for metastatic melanoma.
    Clin Cancer Res. 2022 Nov 15. pii: 710714. doi: 10.1158/1078-0432.CCR-22-2495.
    PubMed     Abstract available

    October 2022
    Too much fuel on the fire? Linking obesity, metabolism and melanoma outcomes.
    Clin Cancer Res. 2022 Oct 31. pii: 710137. doi: 10.1158/1078-0432.CCR-22-3028.
    PubMed     Abstract available

  36. HALL MS, Mullinax JE, Cox CA, Hall AM, et al
    Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.
    Clin Cancer Res. 2022 Oct 10. pii: 709683. doi: 10.1158/1078-0432.CCR-22-2103.
    PubMed     Abstract available

    September 2022
  37. HAHN AW, Menk AV, Rivadeneira DB, Augustin RC, et al
    Obesity is associated with altered tumor metabolism in metastatic melanoma.
    Clin Cancer Res. 2022 Sep 27. pii: 709490. doi: 10.1158/1078-0432.CCR-22-2661.
    PubMed     Abstract available

  38. SHOUSHTARI A, Olszanski AJ, Nyakas M, Hornyak TJ, et al
    Pilot study of ONCOS-102 and pembrolizumab: remodeling of the tumor micro-environment and clinical outcomes in anti-PD1-resistant advanced melanoma.
    Clin Cancer Res. 2022 Sep 16. pii: 709238. doi: 10.1158/1078-0432.CCR-22-2046.
    PubMed     Abstract available

  39. JOHANNET P, Liu W, Fenyo D, Wind-Rotolo M, et al
    Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade.
    Clin Cancer Res. 2022;28:4121-4130.
    PubMed     Abstract available

  40. HASSEL JC, Luke JJ
    Autoantibodies as Predictors for Clinical Outcome and Toxicity for Immunotherapy.
    Clin Cancer Res. 2022;28:3914-3916.
    PubMed     Abstract available

    August 2022
  41. MAO L, Fang M, Chen Y, Wei X, et al
    Atezolizumab Plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: a Multicenter, Open-label, Single-arm Phase 2 Study.
    Clin Cancer Res. 2022 Aug 31. pii: 708943. doi: 10.1158/1078-0432.CCR-22-1528.
    PubMed     Abstract available

    May 2022
    War Against NRAS-mutant Melanoma Using Targeted Therapies Remains Challenging.
    Clin Cancer Res. 2022 May 19. pii: 699070. doi: 10.1158/1078-0432.CCR-22-1256.
    PubMed     Abstract available

  43. BLASS E, Ott PA
    PD-1 inhibition - trouble for subsequent TIL therapy in patients with melanoma?
    Clin Cancer Res. 2022 May 16. pii: 698949. doi: 10.1158/1078-0432.CCR-22-0832.
    PubMed     Abstract available

    March 2022
  44. SASAME J, Ikegaya N, Kawazu M, Natsumeda M, et al
    HSP90 inhibition overcomes resistance to molecular targeted therapy in BRAFV600E mutant high-grade glioma.
    Clin Cancer Res. 2022 Mar 28. pii: 694027. doi: 10.1158/1078-0432.CCR-21-3622.
    PubMed     Abstract available

  45. SHI Q, Liu L, Chen J, Zhang W, et al
    Integrative Genomic Profiling Uncovers Therapeutic Targets of Acral Melanoma in Asian Populations.
    Clin Cancer Res. 2022 Mar 16. pii: 682195. doi: 10.1158/1078-0432.CCR-21-3344.
    PubMed     Abstract available

  46. SCHULER M, Zimmer L, Kim KB, Sosman JA, et al
    Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-Mutant Melanoma.
    Clin Cancer Res. 2022 Mar 16. pii: 682197. doi: 10.1158/1078-0432.CCR-21-3872.
    PubMed     Abstract available

  47. TRIOZZI PL, Stirling ER, Song Q, Westwood B, et al
    Circulating Immune Bioenergetic, Metabolic, and Genetic Signatures Predict Melanoma Patients' Response to Anti-PD-1 Immune Checkpoint Blockade.
    Clin Cancer Res. 2022;28:1192-1202.
    PubMed     Abstract available

  48. LUND AW
    Standing Watch: Immune activation and failure in melanoma sentinel lymph nodes.
    Clin Cancer Res. 2022 Mar 9. pii: 682110. doi: 10.1158/1078-0432.CCR-22-0214.
    PubMed     Abstract available

  49. LI J, Smalley I, Chen Z, Wu JY, et al
    Single cell characterization of the cellular landscape of acral melanoma identifies novel targets for immunotherapy.
    Clin Cancer Res. 2022 Mar 4. pii: 682045. doi: 10.1158/1078-0432.CCR-21-3145.
    PubMed     Abstract available

  50. LEVI ST, Copeland AR, Nah S, Crystal JS, et al
    Neoantigen Identification and Response to Adoptive Cell Transfer in anti PD-1 Naive and Experienced Patients with Metastatic Melanoma.
    Clin Cancer Res. 2022 Mar 3. pii: 681999. doi: 10.1158/1078-0432.CCR-21-4499.
    PubMed     Abstract available

  51. KLEMEN ND, Hwang S, Bradic M, Rosenbaum E, et al
    Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma.
    Clin Cancer Res. 2022;28:939-947.
    PubMed     Abstract available

    February 2022
  52. CREASY CA, Meng YJ, Forget MA, Karpinets T, et al
    Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma.
    Clin Cancer Res. 2022 Feb 18. pii: 681704. doi: 10.1158/1078-0432.CCR-21-1060.
    PubMed     Abstract available

  53. WICHMANN J, Rynn C, Friess T, Petrig-Schaffland J, et al
    Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor.
    Clin Cancer Res. 2022;28:770-780.
    PubMed     Abstract available

    January 2022
  54. YADDANAPUDI K, Stamp BF, Subrahmanyam PB, Smolenkov A, et al
    Single-Cell Immune Mapping of Melanoma Sentinel Lymph Nodes Reveals an Actionable Immunotolerant Microenvironment.
    Clin Cancer Res. 2022 Jan 19. pii: 1078-0432.CCR-21-0664.
    PubMed     Abstract available

  55. PALMER AC, Izar B, Hwangbo H, Sorger PK, et al
    Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors.
    Clin Cancer Res. 2022;28:368-377.
    PubMed     Abstract available

  56. MEHNERT JM, Mitchell T, Huang AC, Aleman TS, et al
    BAMM (BRAF Autophagy and MEK inhibition in Melanoma): A phase I/II trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600-mutant melanoma.
    Clin Cancer Res. 2022 Jan 12. pii: 1078-0432.CCR-21-3382.
    PubMed     Abstract available

    December 2021
  57. WALDSCHMIDT JM, Kloeber JA, Anand P, Frede J, et al
    Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma.
    Clin Cancer Res. 2021;27:6432-6444.
    PubMed     Abstract available

    November 2021
  58. GIRAULT I, Adam J, Shen S, Roy S, et al
    A PD-1 /PD-L1 proximity assay as a theranostic marker for PD-1 blockade in patients with metastatic melanoma.
    Clin Cancer Res. 2021 Nov 16. pii: 1078-0432.CCR-21-1229.
    PubMed     Abstract available

    October 2021
  59. JAMESON-LEE M, Luke JJ
    Ipilimumab Combination Dosing: Less is More.
    Clin Cancer Res. 2021;27:5153-5155.
    PubMed     Abstract available

  60. KRIJGSMAN O, Kemper K, Boshuizen J, Vredevoogd DW, et al
    Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4.
    Clin Cancer Res. 2021;27:5389-5400.
    PubMed     Abstract available

    September 2021
  61. KIM ST, Smith SA, Mortimer P, Loembe AB, et al
    Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer.
    Clin Cancer Res. 2021;27:4700-4709.
    PubMed     Abstract available

    August 2021
  62. SZNOL M
    TIL in Melanoma-Similar Approaches, Different Results, Unanswered Questions.
    Clin Cancer Res. 2021 Aug 19. pii: 1078-0432.CCR-21-2450.
    PubMed     Abstract available

  63. SEITTER SJ, Sherry RM, Yang JC, Robbins PF, et al
    Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma.
    Clin Cancer Res. 2021 Aug 19. pii: 1078-0432.CCR-21-1171.
    PubMed     Abstract available

  64. PARADIS JS, Acosta M, Saddawi-Konefka R, Kishore A, et al
    Correction: Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma.
    Clin Cancer Res. 2021;27:4664.

  65. BAI X, Hu J, Betof Warner A, Quach HT, et al
    Early use of high-dose-glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy.
    Clin Cancer Res. 2021 Aug 10. pii: 1078-0432.CCR-21-1283.
    PubMed     Abstract available

  66. ABBOTT CW, Boyle SM, Pyke RM, McDaniel LD, et al
    Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms.
    Clin Cancer Res. 2021;27:4265-4276.
    PubMed     Abstract available

    July 2021
  67. LONG GV, Robert C, Butler MO, Couture F, et al
    Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules.
    Clin Cancer Res. 2021 Jul 1. pii: 1078-0432.CCR-21-0793.
    PubMed     Abstract available

  68. TSIMBERIDOU AM, Beer PA, Cartwright CA, Haymaker C, et al
    Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors.
    Clin Cancer Res. 2021;27:3584-3594.
    PubMed     Abstract available

    June 2021
  69. MARIN ND, Krasnick BA, Becker-Hapak M, Conant L, et al
    Memory-like differentiation enhances NK cell responses to melanoma.
    Clin Cancer Res. 2021 Jun 29. pii: 1078-0432.CCR-21-0851.
    PubMed     Abstract available

    ATR Inhibitors and Paclitaxel in Melanoma.
    Clin Cancer Res. 2021 Jun 25. pii: 1078-0432.CCR-21-1778.
    PubMed     Abstract available

  71. ASCIERTO PA, Dreno B, Larkin J, Ribas A, et al
    5-Year Outcomes with Cobimetinib Plus Vemurafenib in BRAF (V600) Mutation-Positive Advanced Melanoma: Extended Follow-Up of the coBRIM Study.
    Clin Cancer Res. 2021 Jun 22. pii: 1078-0432.CCR-21-0809.
    PubMed     Abstract available

  72. WEISS SA, Djureinovic D, Jessel S, Krykbaeva I, et al
    A phase I study of APX005M and cabiralizumab with/without nivolumab in patients with melanoma, kidney cancer or non-small cell lung cancer resistant to anti-PD-(L)1.
    Clin Cancer Res. 2021 Jun 17. pii: 1078-0432.CCR-21-0903.
    PubMed     Abstract available

  73. DI GIACOMO AM, Chiarion-Sileni V, Del Vecchio M, Ferrucci PF, et al
    Primary analysis and four-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases.
    Clin Cancer Res. 2021 Jun 10. pii: 1078-0432.CCR-21-1046.
    PubMed     Abstract available

  74. BRASE JC, Walter RFH, Savchenko A, Gusenleitner D, et al
    Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib.
    Clin Cancer Res. 2021 Jun 9. pii: 1078-0432.CCR-20-3586.
    PubMed     Abstract available

  75. MENZIES AM, Scolyer RA, Long GV
    Neoadjuvant immunotherapy in melanoma - the new frontier.
    Clin Cancer Res. 2021 Jun 3. pii: 1078-0432.CCR-21-1236.
    PubMed     Abstract available

  76. HEGDE A, Jayaprakash P, Couillault CA, Piha-Paul S, et al
    A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies.
    Clin Cancer Res. 2021;27:3050-3060.
    PubMed     Abstract available

    May 2021
  77. SMALLEY I, Chen Z, Phadke MS, Li J, et al
    Single cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases.
    Clin Cancer Res. 2021 May 25. pii: 1078-0432.CCR-21-1694.
    PubMed     Abstract available

  78. LOUVEAU B, Resche-Rigon M, Lesimple T, Da Meda L, et al
    Phase I-II open label multicenter study of palbociclib + vemurafenib in BRAFV600MUT metastatic melanoma patients: uncovering CHEK2 as a major response mechanism.
    Clin Cancer Res. 2021 May 4. pii: 1078-0432.CCR-20-4050.
    PubMed     Abstract available

  79. TELLI ML, Nagata H, Wapnir I, Acharya CR, et al
    Intratumoral Plasmid IL12 Expands CD8(+) T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy.
    Clin Cancer Res. 2021;27:2481-2493.
    PubMed     Abstract available

    April 2021
  80. SHAFFER T, Natarajan A, Gambhir SS
    PET Imaging of TIGIT Expression on Tumor-Infiltrating Lymphocytes.
    Clin Cancer Res. 2021;27:1932-1940.
    PubMed     Abstract available

  81. PAPADOPOULOS KP, Autio K, Golan T, Dobrenkov K, et al
    Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors.
    Clin Cancer Res. 2021;27:1904-1911.
    PubMed     Abstract available

    March 2021
    Therapeutic Escape in Galphaq-Mutant Uveal Melanoma: It's a FAK.
    Clin Cancer Res. 2021 Mar 25. pii: 1078-0432.CCR-21-0567.
    PubMed     Abstract available

  83. NAJJAR YG, McCurry D, Lin H, Lin Y, et al
    Neoadjuvant Pembrolizumab and High Dose Interferon Alfa-2b in Resectable Regionally Advanced Melanoma.
    Clin Cancer Res. 2021 Mar 22. pii: 1078-0432.CCR-20-4301.
    PubMed     Abstract available

    February 2021
  84. NGUYEN TT, Ramsay L, Ahanfeshar-Adams M, Lajoie M, et al
    Mutations in the IFNgamma-JAK-STAT pathway causing resistance to immune checkpoint inhibitors in melanoma increase sensitivity to oncolytic virus treatment.
    Clin Cancer Res. 2021 Feb 16. pii: 1078-0432.CCR-20-3365.
    PubMed     Abstract available

  85. KELLY G, Al-Ejeh F, McCuaig RD, Casciello F, et al
    G9a inhibition enhances checkpoint inhibitor blockade response in melanoma.
    Clin Cancer Res. 2021 Feb 15. pii: 1078-0432.CCR-20-3463.
    PubMed     Abstract available

  86. PARADIS JS, Acosta M, Saddawi-Konefka R, Kishore A, et al
    Synthetic Lethal Screens Reveal Co-Targeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma.
    Clin Cancer Res. 2021 Feb 10. pii: 1078-0432.CCR-20-3363.
    PubMed     Abstract available

    January 2021
  87. SHOUSHTARI AN, Chatila WK, Arora A, Sanchez-Vega F, et al
    Therapeutic Implications of Detecting MAP Kinase Activating Alterations in Cutaneous and Unknown Primary Melanomas.
    Clin Cancer Res. 2021 Jan 28. pii: 1078-0432.CCR-20-4189.
    PubMed     Abstract available

  88. MARTINEZ-MORILLA S, Villarroel-Espindola F, Wong PF, Toki MI, et al
    Biomarker Discovery in Immunotherapy-treated Melanoma Patients with Imaging Mass Cytometry.
    Clin Cancer Res. 2021 Jan 27. pii: 1078-0432.CCR-20-3340.
    PubMed     Abstract available

  89. RAHMA OE, Reuss JE, Giobbie-Hurder A, Shoja E Razavi G, et al
    Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors.
    Clin Cancer Res. 2021;27:485-491.
    PubMed     Abstract available

  90. GEIGER T, Beck L, Harel M, Yu S, et al
    Clinical Proteomics of Metastatic Melanoma Reveals Profiles of Organ-Specificity and Treatment Resistance.
    Clin Cancer Res. 2021 Jan 14. pii: 1078-0432.CCR-20-3752.
    PubMed     Abstract available

  91. ATKINS MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, et al
    The State of Melanoma: Emergent Challenges and Opportunities.
    Clin Cancer Res. 2021 Jan 7. pii: 1078-0432.CCR-20-4092.
    PubMed     Abstract available

    December 2020
    MEK-ing the most of it: strategies to co-target Galphaq and MAPK in uveal melanoma.
    Clin Cancer Res. 2020 Dec 22. pii: 1078-0432.CCR-20-4530.
    PubMed     Abstract available

  93. MAKOHON-MOORE AP, Lipson EJ, Hooper JE, Zucker A, et al
    The genetic evolution of treatment-resistant cutaneous, acral and uveal melanomas.
    Clin Cancer Res. 2020 Dec 15. pii: 1078-0432.CCR-20-2984.
    PubMed     Abstract available

  94. MONTFORT A, Filleron T, Virazels M, Dufau C, et al
    Combining nivolumab and ipilimumab with infliximab or certolizumab in patients with advanced melanoma: first results of a phase 1b clinical trial.
    Clin Cancer Res. 2020 Dec 3. pii: 1078-0432.CCR-20-3449.
    PubMed     Abstract available

    November 2020
  95. HITCHMAN TD, Bayshtok G, Ceraudo E, Moore AR, et al
    Combined Inhibition of Galphaq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma.
    Clin Cancer Res. 2020 Nov 23. pii: 1078-0432.CCR-20-2860.
    PubMed     Abstract available

  96. JOHANNET P, Coudray N, Donnelly DM, Jour G, et al
    Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma.
    Clin Cancer Res. 2020 Nov 18. pii: 1078-0432.CCR-20-2415.
    PubMed     Abstract available

  97. MUELLER KL, Theoret MR, Lemery SJ, Amiri-Kordestani L, et al
    Neoadjuvant Therapy for Melanoma: A US Food and Drug Administration - Melanoma Research Alliance Public Workshop.
    Clin Cancer Res. 2020 Nov 13. pii: 1078-0432.CCR-20-3285.
    PubMed     Abstract available

  98. SALAMA AKS, Palta M, Rushing CN, Selim MA, et al
    Ipilimumab and Radiation in Patients with High Risk Resected or Regionally Advanced Melanoma.
    Clin Cancer Res. 2020 Nov 10. pii: 1078-0432.CCR-20-2452.
    PubMed     Abstract available

    October 2020
  99. GANDHI S, Pandey MR, Attwood K, Ji W, et al
    Phase I clinical trial of combination propranolol and pembrolizumab in locally advanced and metastatic melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity.
    Clin Cancer Res. 2020 Oct 30. pii: 1078-0432.CCR-20-2381.
    PubMed     Abstract available

  100. FANE ME, Ecker BL, Kaur A, Marino GE, et al
    sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients.
    Clin Cancer Res. 2020 Oct 23. pii: 1078-0432.CCR-20-0446.
    PubMed     Abstract available

  101. MARSAVELA G, Lee J, Calapre L, Wong SQ, et al
    Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy.
    Clin Cancer Res. 2020 Oct 16. pii: 1078-0432.CCR-20-2251.
    PubMed     Abstract available

  102. CHUA V, Mattei J, Han A, Johnston L, et al
    The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019).
    Clin Cancer Res. 2020 Oct 15. pii: 1078-0432.CCR-20-2536.
    PubMed     Abstract available

    May 2020
  103. PATEL SP, Othus M, Chae YK, Kurzrock R, et al
    Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response.
    Clin Cancer Res. 2020;26:2434.

  104. SONBOL MB, Halfdanarson TR
    Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Letter.
    Clin Cancer Res. 2020;26:2433.

  105. GLITZA OLIVA IC, Tawbi HA
    "Liquid Gold" - The unTAPped Potential of Cerebrospinal Fluid Analysis?
    Clin Cancer Res. 2020;26:2083-2084.
    PubMed     Abstract available

  106. WEBER JS, Postow MA
    TNFalpha Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?
    Clin Cancer Res. 2020;26:2085-2086.
    PubMed     Abstract available

    March 2020
  107. CHUNG JS, Ramani V, Kobayashi M, Fattah F, et al
    DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors.
    Clin Cancer Res. 2020;26:1449-1459.
    PubMed     Abstract available

    February 2020
  108. WATANABE T, Gaedicke S, Guffart E, Firat E, et al
    Adding Indoximod to Hypofractionated Radiotherapy with Anti-PD-1 Checkpoint Blockade Enhances Early NK and CD8(+) T-Cell-Dependent Tumor Activity.
    Clin Cancer Res. 2020;26:945-956.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.